The results from the P-III (COMPASS LTOLE) study & XATOA registry evaluating Xarelto + aspirin in patients (n=27,395 & 5,532) to be published in the ESC. The XATOA registry will also be presented at the ACC 2022
The results from the COMPASS LTOLE showed Xarelto (2.5mg, BID) + Aspirin (75-100mg OD) treatment for 3yrs. was linked to primary outcome event rate incl. CV death, stroke & MI of 2.35 vs 2.18 in the treatment phase along with an increase in bleeding rated during LTOLE of 1.01 vs 1.67 during the randomized phase
The results from the XATOA registry showed similar rates of MACE with the COMPASS trial, rates of major adverse limb events (in males) at 3.57 vs 0.19 & the rate of major bleeding at 0.95 vs 1.7 in the COMPASS trial
Ref: PR Newswire | Image: Janseen
